EUVIMEDEUVIMED entdecken
Crossref

Effective Degradation of Wild‐Type and Mutant EGFR Using Self‐Assembling Peptide‐Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy

Joohee Jeong, Hanhee Cho, Yujeong Moon, Nayeon Shim, Jeongrae Kim, Jinseong Kim, Sungchan Choi, Jung Yeon Park, Yongju Kim, Kwangmeyung Kim iD

Advanced Materials · 2026-02 · 38 (9)

DOI: 10.1002/adma.202516974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 12.12.2025. Verfasst von Joohee Jeong und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Republic of Korea. Hauptthemen laut MEDLINE: ErbB Receptors, Peptides, Nanoparticles, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR)‐targeted therapeutics, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), have achieved clinical success but are limited by drug resistance and off‐target toxicity. Herein, self‐assembling peptide‐derived PROTAC nanoparticles (NanoTACs) engineered for effective degradation of both wild‐type and mutant EGFR for cancer therapy is reported. The NanoTACs are constructed from three peptide components: EGFR‐binding peptide (EHGAMEI), a self‐assembling peptide linker (FF), and an E3 ligase recruiting peptide (ALAPYIP). Through the hydrophobic interaction and π – π stacking, self‐assembling peptide‐derived PROTACs formed uniform spherical nanoparticles with an average diameter of 144 nm under aqueous conditions. In vitro, NanoTACs effectively eliminated both wild‐type and L858R/T790M‐mutant EGFR in cancer cells through direct lysosomal degradation and PROTAC‐driven proteasomal degradation. In vivo, NanoTACs exhibited 2.24‐fold higher tumor‐targeting efficiency than free EGFR‐binding peptide via the enhanced permeability and retention (EPR) effect and EGFR‐mediated active targeting. In colon and lung tumor models, NanoTACs suppressed tumor growth by 88.3%, achieved 95% degradation of wild‐type and 80% of mutant EGFR, and induced extensive apoptosis without systemic toxicity. These findings established NanoTACs as a promising EGFR‐targeted platform to overcome drug resistance to mAbs and TKIs by enabling effective degradation of wild‐type and mutant EGFR in heterogeneous cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsPeptidesNanoparticlesAntineoplastic AgentsNeoplasmsHumansAnimalsCell Line, TumorMiceMutationProteolysisProtein Kinase InhibitorsMice, Nude

Stichwörter der Autor:innen

EGFRPROTACcancer therapydrug deliveryresistanceself‐assembled peptide

Substanzen

ErbB ReceptorsPeptidesAntineoplastic AgentsEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
  • Department of Integrative Energy Engineering, Korea University, Seoul, 02841, Republic of Korea.

ORCID-Profile: Kwangmeyung Kim

Förderung

  • Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Jeong, J., Cho, H., Moon, Y., Shim, N., Kim, J., Kim, J., Choi, S., Park, J. Y., Kim, Y., & Kim, K. (2026). Effective Degradation of Wild‐Type and Mutant EGFR Using Self‐Assembling Peptide‐Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy. Advanced Materials, 38(9). https://doi.org/10.1002/adma.202516974

Vancouver

Jeong J, Cho H, Moon Y, Shim N, Kim J, Kim J, et al. Effective Degradation of Wild‐Type and Mutant EGFR Using Self‐Assembling Peptide‐Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy. Advanced Materials. 2026;38(9). doi:10.1002/adma.202516974

BibTeX
@article{Jeong2026,
  author = {Jeong, Joohee and Cho, Hanhee and Moon, Yujeong and Shim, Nayeon and Kim, Jeongrae and Kim, Jinseong and Choi, Sungchan and Park, Jung Yeon and Kim, Yongju and Kim, Kwangmeyung},
  title = {Effective Degradation of Wild‐Type and Mutant EGFR Using Self‐Assembling Peptide‐Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {9},
  doi = {10.1002/adma.202516974}
}
Kostenlos starten →